Search

Nanjing Tech University has been issued a patent for a cordycepin-based derivatized compound with anti-tumor effects. The compound aims to address the shortcomings of existing nucleoside drugs by combining the natural pharmacological activity of cordycepin. The patent inventors highlight the compound's potential in preventing and treating diseases related to cell functional damage, particularly tumors, and propose a pharmaceutical composition with immune checkpoint inhibitors for enhanced efficacy. [Extracted from the article]

A patent has been issued for anti-SLC34A2 monoclonal antibodies by Lanova Medicines Development Co. Ltd., targeting the sodium-dependent phosphate transporter NaPi2b encoded by the SLC34A2 gene, which is upregulated in cancer cells. These antibodies show high binding affinity to the SLC34A2 protein and are effective in mediating antibody-dependent cellular cytotoxicity and inducing cytotoxicity, making them potential candidates for cancer treatment. The patent details the specific amino acid sequences of the heavy and light chain complementarity determining regions of the antibodies, along with methods for their use in treating diseases like cancer. [Extracted from the article]

Researchers from Genmab B.V. in the Netherlands have highlighted the challenges in using CD3 bispecific antibodies (bsAbs) for solid cancer treatment, such as limited T cell numbers and immunosuppressive tumor environments. They discuss the need for combination strategies to enhance the efficacy of CD3 bsAbs in solid tumors. This research provides valuable insights into improving therapy for solid cancer and offers potential avenues for further study in oncology. [Extracted from the article]

The patent application titled "Stabilized Formulations Containing Anti-BCMA x Anti-CD3 Bispecific Antibodies" discusses the need for stable liquid pharmaceutical formulations of bispecific antibodies targeting BCMA and CD3 for cancer treatment. The formulation includes specific concentrations of antibody, histidine buffer, polysorbate, and sucrose to ensure stability and suitability for patient administration. The patent application emphasizes the importance of proper formulation to maintain stability and effectiveness of therapeutic antibodies. [Extracted from the article]

A recent study conducted at National Taiwan University focused on the use of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in patients with metastatic colorectal cancer (mCRC) who underwent secondary resection after initial treatment. The research found that continuing anti-EGFR monoclonal antibodies post-resection significantly prolonged overall survival for these patients. The study, supported by MERCK KGaA, Darmstadt, concluded that this approach could benefit mCRC patients, regardless of the primary tumor location. The findings were published in the American Journal of Cancer Research and have undergone peer review. [Extracted from the article]

The article discusses the use of bispecific antibodies targeting a specific mutation in chronic lymphocytic leukemia (CLL) to activate T cells and promote killing of cancer cells. These antibodies selectively target the tumor mutation while sparing healthy B cells and stem cells, offering a potential immunotherapy option for high-risk CLL patients. The study suggests that bispecific antibodies could be a promising alternative to CAR T cell therapy for elderly patients who may not tolerate the physical demands of the treatment. [Extracted from the article]

The article discusses a phase 1/2 clinical trial, NCT06819735, evaluating the safety, pharmacokinetics, and efficacy of DT-7012, an anti-CCR8 monoclonal antibody, as a single agent and in combination with an immune checkpoint inhibitor for adult participants with selected advanced solid tumors. The study aims to determine the recommended phase 2 dose and assess anti-tumor activity in participants with recurrent advanced/metastatic solid tumors. The trial is not yet recruiting, with an enrollment target of 60 participants and a completion date of January 2028. [Extracted from the article]

A patent application titled "TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3" was published online by inventors from various locations. The application focuses on developing multispecific antibodies that bind to CD79b, CD20, and CD3 for the treatment of B-cell malignancies, particularly lymphomas. The trispecific antibody aims to address unmet medical needs by targeting multiple antigens simultaneously, potentially improving treatment efficacy and reducing the risk of resistance. The patent application outlines detailed information on the structure and function of the trispecific antibody, along with methods for treating hematological cancers using this innovative therapeutic approach. [Extracted from the article]

A patent has been issued for HER-2 targeted bispecific compositions and methods by Amunix Pharmaceuticals Inc., focusing on T cell engagers for cancer therapy. The patent aims to address challenges such as extreme potency and on-target toxicities in solid tumors, proposing XTENylated protease activated bispecific T cell engagers (XPATs) to improve the therapeutic index. Specifically, the invention introduces AMX-818, a HER2-targeted prodrug TCE designed to enhance safety and efficacy by exploiting dysregulated protease activity in tumors while sparing healthy tissues. [Extracted from the article]

Dragonfly Therapeutics Inc. has been issued a patent for multi-specific binding proteins that bind to CD33 on cancer cells, as well as the NKG2D and CD16 receptors on natural killer cells. These proteins aim to enhance the activity of natural killer cells in destroying cancer cells, particularly those associated with hematopoietic cancers like acute myeloid leukemia. The patent details the specific amino acid sequences and structures of the proteins, highlighting their potential therapeutic applications in cancer treatment. [Extracted from the article]

Researchers from Peking University Cancer Hospital and Institute conducted a phase II trial to evaluate the efficacy and safety of the anti-PD-L1/CTLA-4 bispecific antibody KN046 combined with lenvatinib in patients with advanced hepatocellular carcinoma (HCC). The study included fifty-five participants and found promising results, with an objective response rate of 45.5% and a median overall survival of 16.4 months. The research concluded that circulating tumor DNA status before the third cycle of treatment was associated with prognosis, indicating that the combination therapy shows potential for treating advanced HCC. [Extracted from the article]

Yonsei University researchers have released new data on xenografts, specifically focusing on the use of anti-PTK7 monoclonal antibodies to suppress oncogenic phenotypes in cellular and xenograft models of triple-negative breast cancer (TNBC). The study highlights the potential of PTK7 as a therapeutic target in TNBC and demonstrates the anti-cancer effects of PTK7-neutralizing monoclonal antibodies both in vitro and in vivo. Further research on PTK7-targeted therapies, such as humanized monoclonal antibodies and antibody-drug conjugates, is recommended to advance treatment strategies for PTK7-positive TNBC. [Extracted from the article]

A patent application titled "Complement Factor H Antibodies" has been published online, focusing on the development of isolated antibodies that bind to Complement Factor H (CFH) protein. The invention aims to target CFH to enhance complement-dependent lysis of tumor cells, potentially impacting the adaptive immune response against cancer, particularly lung cancer. The patent application outlines the amino acid sequences of the antibodies and their potential therapeutic applications in inhibiting tumor growth and increasing complement-dependent lysis of cells. [Extracted from the article]

Researchers at Tianjin University of Traditional Chinese Medicine have conducted a study on precision therapy for relapsed/refractory multiple myeloma. The study emphasizes the importance of individualized treatment regimens for patients with RRMM, incorporating multidrug combinations and cutting-edge immunotherapeutic drugs. The research suggests that new generation drugs and monoclonal antibodies are key components of treatment for RRMM patients, with the potential for deep remissions and long-term survival. This study was supported by the National Natural Science Foundation of China and has been peer-reviewed, offering valuable insights into the latest advancements in multiple myeloma treatment. [Extracted from the article]

Researchers have submitted a patent application for a Tlr8 agonist aimed at modulating immune responses, particularly in enhancing immunity in humans. The compound described in the patent can be used alone or as an adjuvant in vaccines for various diseases, including cancer, infectious diseases, and autoimmune conditions. The patent application highlights the potential of the compound to stimulate both innate and adaptive immune responses, offering promising avenues for effective immunization, especially in vulnerable populations. [Extracted from the article]

Researchers have submitted a patent application for a bispecific antibody that can engage two different antigenic epitopes simultaneously, showing potential in antibody engineering and oncology immunotherapy. The patent application addresses challenges in the production of bispecific antibodies, focusing on reducing mispairing between heavy and light chains to improve efficiency. The application details specific mutations introduced into the antibody structure to enhance its functionality and yield. For more information, refer to the full patent application titled "Bispecific Antibody And Use Thereof" filed on September 23, 2022, and posted on February 6, 2025. [Extracted from the article]

Researchers at Fujian Medical University have conducted a study on gastric cancer, focusing on the relationship between cancer development and alterations in IgG N-glycosylation. The study utilized high-throughput mass spectrometry to characterize IgG N-glycome in gastric cancer and identified subclass-specific changes in IgG galactosylation and sialylation. The research suggests that subclass-specific IgG N-glycosylation could serve as promising biomarkers for detecting and monitoring gastric cancer progression, potentially influenced by cytokine-driven inflammation. This study provides insights into the molecular mechanisms of gastric cancer, which could lead to diagnostic improvements and therapeutic developments. [Extracted from the article]

Researchers from Johns Hopkins University School of Medicine have conducted a study on myositis, a group of autoimmune diseases characterized by muscle inflammation. The study focused on anti-melanoma differentiation-associated protein 5 (MDA5) and anti-signal recognition particle (SRP) positive myositis, finding a potential link between enterovirus infection and anti-MDA5 dermatomyositis. The research, supported by the National Institutes of Health and the Jerome L. Greene Foundation, analyzed serum antibodies in patients with these conditions and healthy controls, revealing specific immunogenic regions within the MDA5 and SRP autoantigens. The findings suggest a novel etiological connection between enterovirus infection and anti-MDA5 dermatomyositis. [Extracted from the article]

Researchers have submitted a patent application for "Anti-Cd40 Antibodies And Uses Thereof" to develop anti-cancer antibodies for therapeutic use in treating cancers. The application focuses on antibodies that bind to CD40, a protein associated with cancer, and includes detailed information on amino acid sequences and nucleic acids encoding these antibodies. The patent application aims to address the high mortality rates associated with cancer globally, emphasizing the need for innovative antibody-based therapeutics. [Extracted from the article]

A patent application titled "Proteins And Use Thereof" was published online by inventors from Shanghai, China, on January 30, 2025. The application focuses on the development of isolated antibodies capable of binding to Vascular Endothelial Growth Factor A (VEGF-A), transferrin, and properdin for potential therapeutic applications in diseases such as cancer and age-related macular degeneration. The document discusses the importance of inhibiting VEGF and properdin in disease treatment, as well as the challenges and advancements in drug delivery systems, particularly for biologics. The patent application highlights the potential of these proteins in targeted therapies and the modulation of the complement system for various human diseases. [Extracted from the article]

A patent application by inventors from the Children's Hospital of Philadelphia focuses on using anti-tumor CAR molecules and bispecific innate immune cell engagers (BICE) to activate host innate immune effector cells in pediatric malignancies, particularly high-risk neuroblastoma. The invention aims to address the limitations of CAR T-cell efficacy in pediatric solid tumors due to heterogeneous antigen expression and immunosuppressive tumor microenvironments. The patent application details polynucleotides encoding chimeric antigen receptors (CAR) and fusion proteins, along with methods for treating cancer by administering these cells or compositions to activate innate immune effector cells against the cancer. [Extracted from the article]

A patent application titled "Anti-Pd-1 Antibodies And Uses Thereof" was published online by inventors from Beijing, China, on January 30, 2025. The application focuses on developing anti-PD-1 antibodies for use in antibody-based therapeutics to treat cancer. The disclosure includes details on the amino acid sequences of the antibodies and their potential applications in cancer treatment. The patent application emphasizes the need for innovative antibody-based therapies in the field of oncology. [Extracted from the article]

A recent study from Chongqing Medical University explores the diagnostic and prognostic roles of decreased autoantibodies in lung cancer. Researchers identified 15 types of decreased autoantibodies, with 6 of them forming a predictive model for early lung cancer diagnosis. The study also found that some of these autoantibodies could be used to monitor bone metastasis in lung adenocarcinoma. The research highlights the importance of decreased autoantibodies in lung cancer, offering new diagnostic and therapeutic possibilities. [Extracted from the article]

The patent application titled "Antigen-Binding Domains And Methods Of Use Thereof" discusses the development of chimeric antigen receptor (CAR) therapy for acute myeloid leukemia (AML) by targeting human endomucin (EMCN). The therapy aims to redirect the specificity and function of immunoresponsive cells, such as T cells, to treat hematological malignancies effectively. The patent application outlines the amino acid sequences of the antibody binding fragments and chimeric proteins involved in this therapy, emphasizing the need for suitable targets to avoid damaging normal cells expressing the same target antigen. [Extracted from the article]

A recent study from the City of Hope National Medical Center in Duarte, California, highlights the significant impact of bispecific antibody therapy on the treatment of hematologic malignancies. This therapy involves redirecting T-cells to target immune cells towards tumor-associated antigens, showing promise in various hematologic cancers. The study emphasizes the need for further research to explore the full potential and benefits of these therapies in treating hematologic malignancies. [Extracted from the article]

The article discusses a phase I clinical trial, NCT06802523, testing the safety and efficacy of lintuzumab-Ac225 in combination with venetoclax and ASTX-727 for treating newly diagnosed acute myeloid leukemia (AML). Lintuzumab-Ac225 is a monoclonal antibody linked to a radioactive agent that targets cancer cells, while venetoclax and ASTX-727 are medications that inhibit cancer cell growth and promote normal blood cell production. The trial aims to determine the best dose of the combination treatment and its impact on remission rates and survival. The study is still in the recruitment phase, with a focus on adult patients with AML. [Extracted from the article]

Researchers have submitted a patent application for the use of Semaphorin-4D antibodies in combination with immune modulating therapy to inhibit tumor growth and metastasis. The patent application addresses the need for safe and effective cancer treatments that can either act alone or in combination with other therapies to reduce tumor growth. The method involves administering an isolated binding molecule that specifically binds to SEMA4D and an immune modulating therapy to inhibit, delay, or reduce tumor growth in subjects with cancer. The patent application was filed by Vaccinex Inc. and provides detailed information on the potential treatment approach. [Extracted from the article]